Research programme: AL-amyloid fibrillogenesis inhibitors - NeurochemAlternative Names: AL-amyloid fibrillogenesis inhibitors research programme - Neurochem
Latest Information Update: 02 May 2008
At a glance
- Originator Neurochem
- Developer BELLUS Health
- Mechanism of Action Amyloid fibril protein AL inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Amyloidosis
Most Recent Events
- 02 May 2008 Discontinued - Preclinical for Amyloidosis in Canada (PO)
- 07 Jul 2006 No development reported - Preclinical for Amyloidosis in Canada (PO)
- 20 Jul 2000 Preclinical development for Amyloidosis in Canada (PO)